| Class | SSRI |
|---|---|
| Chemistry |
Bicyclic phthalene derivative
|
| Routes of administration |
Oral only |
| Absorption |
Complete and rapid absorption; almost 100% bioavailability
|
| Solubility |
pKa 9.7, poorly water-soluble
|
| Distribution |
VOD=12L/kg; 80% protein-bound
|
| Metabolism |
Hetaptic metabolism by N-demethylation into several active metabolites
|
| Elimination |
50% of the metabolites are renally excreted, and 50% of them are eliminated in the faeces, suggesting that there is some biliary excretion.
|
| Time course of action |
Half life is about 36 hours
|
| Target receptor |
Serotonin reuptake transport protein (SCL6A4, or SERT) - highly selective for this protein, with minimal noradrenergic effects |
| Mechanism of action |
By inhibiting the reuptake of serotonin from the synaptic cleft, SSRIs increase serotonergic neurotransmission, which is thought to be involved in mood regulation. |
| Clinical effects |
Agitation, diarrhoea, loss or gain of weight, vertigo; risk of serotonin syndrome with overdose |
| Literature reference |
Hiemke & Härtter (2000) |
| CICM details of understanding | Not specifically listed in the CICM syllabus |
| Mentioned around Deranged Physiology | |
| Related SAQs |